Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Personalis Inc

PSNL ✗ NOT COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Small Cap Analyst: BUY

Last Close

$14.04

▼ -2.64%

Market Cap $1.50B · Vol 299.59K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$1.50B

Small Cap

Div Yield

N/A

EPS Growth

-12.75%

YoY

RSI (14)

69.58

Momentum

Beta

2.28

vs Market

52W High

$16.39

14.34% below

52W Low

$4.44

216.22% above

Volume

299.59K

Avg 1.41M

P/B

3.12

Price-to-book

ROE

-35.02%

Return on equity

Free Float

72.53%

Public shares

Shariah Compliance8 STANDARDS

✗ Personalis Inc (PSNL) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does PSNL pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-0.85%

-6.59%

+109.24%

+71.01%

YTD

+76.38%

+201.29%

+675.69%

-23.19%

Financials & Valuation

TTM · Annual

Total Revenue	$69.65M
Net Income	$-81,270,000.00
Revenue Growth (YoY)	+29.96%
Gross Margin	22.65%
Operating Margin	-126.43%
Net Profit Margin	-116.69%
ROE	-35.02%
ROA · ROIC	-26.88% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	10.20
P/B	3.12
P/FCF	N/A
EPS Growth	-12.75%
Outstanding Shares	106.80M

Technical Indicators

50-Day SMA	$12.66
200-Day SMA	$9.27
RSI (14)	69.58
Beta	2.28
52-Week High	$16.39
52-Week Low	$4.44

Volume Today	299.59K
Avg Daily Volume (30D)	1.41M
Relative Volume	0.21x
Volatility (10D)	55.53
Volatility (30D)	69.77
Free Float	72.53%

Analyst Consensus

BUY

Current Price $14.04

Mean Target $13.88

52W Low$4.44 52W High$16.39

Current

Target

$4.44 $16.39

Current Analyst target

-1.18% downside risk · 7 analysts

Identifiers

ExchangeNasdaq

FIGIBBG0027NWBS7

ISINUS71535D1063

CountryUnited States of America

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateNov 2, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG -1.78% RVMD Revolution Medicines Inc +0.85% ONC BeOne Medicines AG -2.40% 068270.KS Celltrion Inc -0.50% ABVX Abivax SA -2.05%

Company Profile

Personalis, Inc. is engaged in developing, marketing and selling advanced cancer genomic tests and analytics. The Company’s advanced genomic sequencing and analytics support the development of personalized cancer vaccines and other cancer immunotherapies. Its products include NeXT Personal, ImmunoI DNeXT, NeXT Personal Dx, NeXT Dx, whole exome sequencing (WES), and whole genome sequencing (WGS). NeXT Personal is a tumor-informed liquid biopsy test for the detection of minimal residual disease (MRD) and recurrence in cancer. NeXT Dx is a comprehensive tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient. The Company performed WGS on human samples for research projects, such as population sequencing initiatives. The Company’s tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and the development of personalized cancer therapies.